会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 82. 发明申请
    • HDL-ASSOCIATED PROTEIN EXTRACTION AND DETECTION
    • 高密度脂蛋白相关蛋白提取和检测
    • US20160084856A1
    • 2016-03-24
    • US14858111
    • 2015-09-18
    • Cleveland HeartLab, Inc.
    • Cory BystromTimothy Collier
    • G01N33/92
    • G01N33/92G01N2333/775
    • Provided herein are compositions, systems, and methods for extracting and detecting at least one HDL-associated protein (e.g., ApoA1) from a sample (e.g., plasma or serum sample). In certain embodiments, a strong organic acid and hydrophilic organic solvent are mixed with the sample; after centrifugation, the supernatant is transferred to a second container where it is mixed with a non-polar organic solvent; after centrifugation, the lower aqueous layer is transferred to a third container; and then at least a portion of the transferred aqueous layer is subjected to a detection assay such that at least one HDL-associated protein is detected.
    • 本文提供了用于从样品(例如血浆或血清样品)提取和检测至少一种HDL相关蛋白(例如ApoA1)的组合物,系统和方法。 在某些实施方案中,将强有机酸和亲水性有机溶剂与样品混合; 离心后,将上清转移到第二容器中,在其中与非极性有机溶剂混合; 离心后,将下层水层转移到第三容器中; 然后将至少一部分转移的水层进行检测测定,使得至少检测到一种HDL相关蛋白。
    • 85. 发明申请
    • RAPID TESTS FOR INSURANCE UNDERWRITING
    • 保险承诺的快速检测
    • US20160003819A1
    • 2016-01-07
    • US14427972
    • 2013-09-11
    • FORCE DIAGNOSTICS, INC
    • Michael P. CURRANDavid H. OSTROWBrian MULCONREYTedd C. DETERMAN
    • G01N33/558G01N33/72G01N33/68G01N33/569G01N33/576
    • G01N33/558G01N33/56988G01N33/57434G01N33/576G01N33/6854G01N33/723G01N2333/4737G01N2333/58G01N2333/775G01N2800/08
    • The present invention relates to rapid test devices, kits and systems comprising the rapid test devices for assessing at least two analytes in a sample derived from a life or health insurance applicant, said at least two analytes being selected from the group consisting of a human immunodeficiency virus (HIV) antigen (e.g., a HIV polypeptide), a HIV polynucleotide, an anti-HIV antibody, a hepatitis C virus (HCV) antigen (e.g., a HCV polypeptide), a HCV polynucleotide, an anti-HCV antibody, a liver enzyme alanine transaminase (ALT), a liver enzyme aspartate transaminase (AST), nt-probnp (or NT-proBNP), probnp (or proBNP), cotinine, nicotine, cocaine, a metabolite of cocaine (e.g., benzoylecgonine), pro state-specific antigen (PSA), apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB), Hemoglobin Ale and high-sensitivity C-reactive protein (hsCRP). The present invention also relates to methods for using the rapid test devices, kits and systems as part of the assessment of the life or health insurance applications.
    • 本发明涉及快速测试装置,试剂盒和系统,其包括用于评估来自生命或健康保险申请人的样品中的至少两种分析物的快速测试装置,所述至少两种分析物选自人免疫缺陷 病毒(HIV)抗原(例如,HIV多肽),HIV多核苷酸,抗HIV抗体,丙型肝炎病毒(HCV)抗原(例如,HCV多肽),HCV多核苷酸,抗HCV抗体, 肝酶丙氨酸转氨酶(ALT),肝酶天冬氨酸转氨酶(AST),nt-probnp(或NT-proBNP),probnp(或proBNP),可替宁,尼古丁,可卡因,可卡因的代谢物(例如苯并恶唑) 状态特异性抗原(PSA),载脂蛋白A-1(ApoA1),载脂蛋白B(ApoB),血红蛋白Ale和高敏C反应蛋白(hsCRP)。 本发明还涉及使用快速测试装置,套件和系统作为对生命或健康保险应用的评估的一部分的方法。
    • 88. 发明授权
    • Methods of predicting and decreasing the risk of pregnancy loss
    • 预防和减少妊娠损失风险的方法
    • US09068990B2
    • 2015-06-30
    • US14276601
    • 2014-05-13
    • University of Louisville Research Foundation, Inc.
    • Douglas D. TaylorCicek Gercel-Taylor
    • G01N33/68
    • G01N33/689G01N2333/775G01N2333/78G01N2800/50
    • Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the absence or a non-detectable level of antibodies specifically binding to alpha2M is associated with a history of RPL and an increased risk of pregnancy loss. Also described are methods for identifying subjects at risk of pregnancy loss, selecting subjects for participation in a clinical study, and methods of decreasing the risk of pregnancy loss in a subject which include detecting the presence or absence of antibodies to one or more of trophoblast-derived ApoB-100, alpha2M, and fibronectin. Also provided are kits that contain ApoB-100, alpha2M, and fibronectin.
    • 基于对三种蛋白质,载脂蛋白B-100,α2巨蛋白酶(α2M)和纤连蛋白的异常体液应答的存在,描述了用于诊断和预测受试者的妊娠损失风险的方法。 来自滋养细胞衍生的纤连蛋白和/或ApoB-100的母体IgG抗体的存在或可检测水平,和/或与α2M特异性结合的不存在或不可检测水平的抗体与RPL的历史和增加的风险相关 的怀孕损失。 还描述了用于鉴定患有妊娠损失风险的受试者的方法,选择参与临床研究的受试者以及降低受试者妊娠损失风险的方法,其中包括检测对滋养层细胞的一种或多种的抗体的存在或不存在, 衍生的ApoB-100,α2M和纤连蛋白。 还提供了含有ApoB-100,α2M和纤连蛋白的试剂盒。